A detailed history of Morgan Stanley transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 7,477,397 shares of TSHA stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,477,397
Previous 5,168,890 44.66%
Holding current value
$10.2 Million
Previous $14.8 Million 12.91%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 17, 2024

BUY
$2.04 - $4.17 $4.71 Million - $9.63 Million
2,308,507 Added 44.66%
7,477,397 $16.7 Million
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $4.71 Million - $9.63 Million
2,308,507 Added 44.66%
7,477,397 $16.7 Million
Q1 2024

Oct 17, 2024

SELL
$1.43 - $3.25 $3.3 Million - $7.5 Million
-2,308,507 Reduced 30.87%
5,168,890 $14.8 Million
Q1 2024

Aug 16, 2024

BUY
$1.43 - $3.25 $7.08 Million - $16.1 Million
4,952,352 Added 2287.06%
5,168,890 $14.8 Million
Q1 2024

May 15, 2024

BUY
$1.43 - $3.25 $7.08 Million - $16.1 Million
4,952,352 Added 2287.06%
5,168,890 $14.8 Million
Q4 2023

Aug 16, 2024

SELL
$1.33 - $2.88 $9.66 Million - $20.9 Million
-7,260,859 Reduced 97.1%
216,538 $383,000
Q4 2023

Feb 13, 2024

BUY
$1.33 - $2.88 $59,143 - $128,070
44,469 Added 25.84%
216,538 $383,000
Q3 2023

Nov 15, 2023

BUY
$0.63 - $3.66 $25,679 - $149,185
40,761 Added 31.04%
172,069 $543,000
Q2 2023

Aug 14, 2023

BUY
$0.59 - $0.87 $25,662 - $37,840
43,495 Added 49.53%
131,308 $86,000
Q1 2023

May 15, 2023

BUY
$0.65 - $2.3 $41,733 - $147,673
64,206 Added 271.98%
87,813 $70,000
Q4 2022

Feb 14, 2023

SELL
$1.39 - $2.98 $1,883 - $4,037
-1,355 Reduced 5.43%
23,607 $53,000
Q3 2022

Nov 14, 2022

SELL
$1.76 - $4.94 $82,172 - $230,643
-46,689 Reduced 65.16%
24,962 $48,000
Q2 2022

Oct 27, 2022

SELL
$2.47 - $6.77 $257,136 - $704,784
-104,104 Reduced 59.23%
71,651 $265,000
Q2 2022

Aug 15, 2022

SELL
$2.47 - $6.77 $257,136 - $704,784
-104,104 Reduced 59.23%
71,651 $265,000
Q1 2022

Oct 27, 2022

BUY
$5.22 - $11.86 $543,422 - $1.23 Million
104,104 Added 145.29%
175,755 $1.15 Million
Q1 2022

May 13, 2022

BUY
$5.22 - $11.86 $174,400 - $396,242
33,410 Added 23.47%
175,755 $1.15 Million
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $197,178 - $331,219
17,251 Added 13.79%
142,345 $1.66 Million
Q3 2021

Nov 15, 2021

BUY
$15.82 - $21.57 $1.98 Million - $2.7 Million
125,094 New
125,094 $2.33 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $66.3M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.